Plain-English translation of NCT06864403 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a medication called mirikizumab can help treat chronic inflammation of the pouch—a surgically created pouch that some people have after bowel surgery. Researchers want to see if this medication reduces painful symptoms like abdominal pain, urgency, bleeding, and discomfort. The medication is given as an injection once every 4 weeks for one year.
Some people who have pouch surgery develop ongoing inflammation that doesn't respond well to antibiotics or keeps coming back. This medication may offer a new option for people whose symptoms are hard to control with current treatments.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the medication once every 4 weeks for one full year. You'll visit the clinic once a month for the first two months, then again at the end of the study year. Throughout the study, you'll keep a daily diary of your pouch symptoms so researchers can track whether the medication is helping reduce your pain, urgency, bleeding, and other discomfort.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United States